Paracetamol Accord 1000 mg comprimate efervescente

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Multiple sclerosis (MS)Progressive multiple sclerosis (PMS)

Phase 3

A Single Arm, Open Label Multicentre Extension Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trial

CompletedCTIS2023-506543-41-00

F. Hoffmann-La Roche AGMultiple sclerosis (MS)

Start: 2018-07-25End: 2025-04-22Target: 645Updated: 2025-06-16

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis

Active, not recruitingCTIS2023-506429-13-00

F. Hoffmann-La Roche AGProgressive multiple sclerosis (PMS)

Start: 2018-05-02Target: 520Updated: 2025-08-25